New Immunotherapy for Small Cell Lung Cancer Impresses in Phase II Clinical Trial

KREMS, Austria - Nov. 23, 2023 - PRLog -- Results from a recently published phase II clinical trial of an immunotherapeutic agent (Tarlatamab) for the treatment of small cell lung cancer have demonstrated anti-tumor activity and a promising extension of overall survival in patients. The international study (DeLLphi-301) was conducted at 56 clinical centers in 17 countries. The University Hospital Krems of the Karl Landsteiner University of Health Sciences (KL Krems) played a particularly active role, treating numerous patients from Austria, Switzerland and the Czech Republic. Tarlatamab was evaluated as a possible treatment alternative for patients previously considered to be beyond treatment – and the results now available are promising in this respect.

Small cell lung carcinoma is a serious disease associated with poor survival. Although most patients respond to first- and second-line treatment, the disease usually progresses within a few months. However, options for subsequent third-line treatment are very limited as there are currently no approved drugs. The clinical evaluation of a new immunotherapeutic agent from Amgen Inc. offers hope. After a successful phase I trial, the results of the subsequent phase II trial were eagerly awaited – and have now been published in New England Journal of Medicine.

Original publication: https://kris.kl.ac.at/en/publications/tarlatamab-for-pati...

Scientific Contact

OA Dr. Sabin Handzhiev

Department of Pneumology

University Hospital Krems

Karl Landsteiner University of Health Sciences

Mitterweg 10

3500 Krems / Austria

T +43 2732 9004 12955

E sabin.handzhiev@krems.lknoe.at

W https://krems.lknoe.at

Copy Editing & Distribution

PR&D – Public Relations for Research & Education

Dr. Barbara Bauder

Kollersteig 68

3400 Klosterneuburg / Austria

M +43 664 1576 350

E bauder@prd.at

W https://www.prd.at/